CurifyLabs has announced the completion of a $14 million Series A financing round to support the expansion of its personalized medicine platform and accelerate growth in the United States. The round was co-led by Sandwater and HealthCap, with participation from Tesi (Finnish Industry Investment Ltd.) and existing investors, including Lifeline Ventures. U.S. customers and employees also participated in the financing.
The company said the proceeds will be used to expand U.S. operations, strengthen supply chain infrastructure, enhance customer support, and accelerate product innovation as demand for its technology continues to grow.
CurifyLabs has developed its Compounding System Solution (CSS), which combines proprietary software, GMP-manufactured excipient bases, and advanced 3D printing technology to automate the preparation of personalized medicines. The platform incorporates quality control processes designed to produce tailored doses and dosage forms with greater precision and speed than traditional manual pharmacy compounding.
The company's technology is currently used by pharmacies across 21 U.S. states and throughout Europe, where it supports the compounding and dispensing of thousands of personalized doses each day. As its customer base expands, CurifyLabs plans to further invest in its supply chain to ensure pharmacy partners have consistent access to required materials.
Commenting on the investment, Morten E. Iversen, partner at Sandwater, said, “Personalized medicine is one of the most important frontiers in healthcare enabling better patient outcomes and is experiencing solid growth. We are enabling more pharmacies to deliver personalized medicine in a safer and more efficient way. CurifyLabs has built something rare technology that combines clinical rigor with the speed and precision that busy pharmacy teams depend on. We are excited to support their rapid growth in the U.S. and beyond.”
Daniel Karsberg, partner at HealthCap, added, “We have backed more than 136 life sciences companies over nearly three decades, and what sets the best founders apart is their ability to combine scientific depth with real-world execution. The CurifyLabs team has done exactly that.”
Joni Karsikas, Investment Director at Tesi, said, “CurifyLabs is the kind of company we want to support innovative, globally ambitious, and built on deep scientific expertise. Their growth in the U.S. is further proof that Finnish health technology can compete and win on the world stage.”
Charlotta Topelius, CEO and Founder of CurifyLabs, said, “This investment reflects the conviction our partners have in what we’re building. We have set a high bar for clinical rigor, product quality, and customer support, and this funding gives us the resources to raise that bar further.”
The funding will also support continued development of the CurifyLabs platform, including the PharmaPrinter Aurum, which compounds medications up to nine times faster than manual processes. The company's technology is ISO 13485 certified and designed in compliance with FDA 503A/503B standards for non-sterile compounding.
Click here for the original news story.
